Safety and efficacy of fecal microbiota transplantation (FMT) as a modern adjuvant therapy in various diseases and disorders: a comprehensive literature review
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Сен. 26, 2024
The
human
gastrointestinal
(GI)
tract
microbiome
is
a
complex
and
all-encompassing
ecological
system
of
trillions
microorganisms.
It
plays
vital
role
in
digestion,
disease
prevention,
overall
health.
When
this
delicate
balance
disrupted,
it
can
lead
to
various
health
issues.
Fecal
microbiota
transplantation
(FMT)
an
emerging
therapeutic
intervention
used
as
adjuvant
therapy
for
many
diseases,
particularly
those
with
dysbiosis
their
underlying
cause.
Its
goal
restore
by
transferring
fecal
material
from
healthy
donors
the
recipients.
FMT
has
impressive
reported
cure
rate
between
80%
90%
become
favored
treatment
diseases.
While
may
have
generally
mild
moderate
transient
adverse
effects,
rare
severe
complications
underscore
importance
rigorous
donor
screening
standardized
administration.
enormous
potential
practical
approach;
however,
additional
research
required
further
determine
its
clinical
utilization,
well
safety
efficiency
different
patient
populations.
This
comprehensive
literature
review
offers
increased
confidence
effectiveness
several
diseases
affecting
intestines
other
systems,
including
diabetes,
obesity,
inflammatory
autoimmune
illness,
conditions.
Язык: Английский
From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy
Gut Microbes,
Год журнала:
2025,
Номер
17(1)
Опубликована: Янв. 18, 2025
The
integration
of
fecal
microbiota
transplantation
(FMT)
with
immune
checkpoint
inhibitors
(ICIs)
presents
a
promising
approach
for
enhancing
cancer
treatment
efficacy
and
overcoming
therapeutic
resistance.
This
review
critically
examines
the
controversial
effects
FMT
on
ICIs
outcomes
elucidates
underlying
mechanisms.
We
investigate
how
modulates
gut
composition,
microbial
metabolite
profiles,
tumor
microenvironment,
thereby
influencing
effectiveness.
Key
factors
efficacy,
including
donor
selection
criteria,
recipient
characteristics,
administration
protocols,
are
comprehensively
discussed.
delineates
strategies
optimizing
formulations
systematically
monitoring
post-transplant
microbiome
dynamics.
Through
comprehensive
synthesis
evidence
from
clinical
trials
preclinical
studies,
we
elucidate
potential
benefits
challenges
combining
across
diverse
types.
While
some
studies
report
improved
outcomes,
others
indicate
no
benefit
or
adverse
effects,
emphasizing
complexity
host-microbiome
interactions
in
immunotherapy.
outline
critical
research
directions,
encompassing
need
large-scale,
multi-center
randomized
controlled
trials,
in-depth
ecology
multi-omics
approaches
artificial
intelligence.
Regulatory
ethical
addressed,
underscoring
imperative
standardized
protocols
rigorous
long-term
safety
assessments.
seeks
to
guide
future
endeavors
applications
FMT-ICIs
combination
therapy,
improve
patient
while
ensuring
both
efficacy.
As
this
rapidly
evolving
field
advances,
maintaining
judicious
balance
between
openness
innovation
cautious
scrutiny
is
crucial
realizing
full
modulation
Язык: Английский
Assessing microbiota in vivo: debugging with medical imaging
Trends in Microbiology,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Digging deeper into necrotizing enterocolitis: bridging clinical, microbial, and molecular perspectives
Gut Microbes,
Год журнала:
2025,
Номер
17(1)
Опубликована: Янв. 18, 2025
Necrotizing
Enterocolitis
(NEC)
is
a
severe,
life-threatening
inflammatory
condition
of
the
gastrointestinal
tract,
especially
affecting
preterm
infants.
This
review
consolidates
evidence
from
various
biomedical
disciplines
to
elucidate
complex
pathogenesis
NEC,
integrating
insights
clinical,
microbial,
and
molecular
perspectives.
It
emphasizes
modulation
NEC-associated
pathways
by
probiotics
novel
biologics,
highlighting
their
therapeutic
potential.
We
further
critically
examine
dysbiotic
alterations
within
gut
microbiota,
with
particular
focus
on
imbalances
in
bacterial
viral
communities,
which
may
contribute
onset
NEC.
The
intricate
interactions
among
toll-like
receptor
4
(TLR4),
microvascular
integrity,
immune
activation,
milieu
are
meticulously
summarized,
offering
sophisticated
understanding
NEC
pathophysiology.
academic
aims
enhance
etiological
comprehension
promote
development
targeted
interventions,
impart
significant
impact
perinatal
factors
formulation
preventive
curative
strategies
for
disease.
Язык: Английский
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases
Expert Opinion on Biological Therapy,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 26, 2025
The
microbiota
composition
in
humans
varies
according
to
the
anatomical
site
and
is
crucial
for
maintaining
homeostasis
an
overall
healthy
state.
Several
gastrointestinal,
vaginal,
respiratory,
skin
diseases
are
associated
with
dysbiosis.
Alternative
therapies
such
as
transplantation
can
help
restore
normal
be
implemented
treat
clinically
relevant
diseases.
Current
conducted
clinical
trials
were
included
this
review
(after
searching
on
MEDLINE
database
from
years
2017
2025)
fecal
(FMT)
against
recurrent
Clostridiodes
difficile
infection
(rCDI)
vaginal
(VMT)
bacterial
vaginosis.
Washed
(WMT)
live
biotherapeutic
products
(LBPs)
also
reviewed.
In
microbiota-based
therapy,
selecting
optimal
donors
a
limitation.
A
stool
or
bank
should
overcome
time-consuming
expensive
process
of
donor
recruitment.
Microbiota-based
LBPs
promising
treatment
alternatives
rCDI
other
dysbiosis-associated
Specific
could
engineered
out
fluids-derived
strains
achieve
selection
specific
beneficial
microorganisms
Personalized
treatments
solutions
diseases,
which
remains
important
necessity
practice.
Язык: Английский
Translational strategies for oral delivery of faecal microbiota transplantation
Gut,
Год журнала:
2025,
Номер
unknown, С. gutjnl - 335077
Опубликована: Апрель 29, 2025
Faecal
microbiota
transplantation
(FMT)
has
emerged
as
a
transformative
therapy
for
Clostridioides
difficile
infections
and
shows
promise
various
GI
systemic
diseases.
However,
the
poor
patient
acceptability
accessibility
of
‘conventional’
FMT,
typically
administered
via
colonoscopies
or
enemas,
hinders
its
widespread
clinical
adoption,
particularly
chronic
conditions.
Oral
administration
FMT
(OralFMT)
overcomes
these
limitations,
yet
faces
distinct
challenges,
including
significant
capsule
burden,
palatability
concerns
microbial
viability
during
gastric
transit.
This
review
provides
comprehensive
analysis
emerging
strategies
that
aim
to
advance
OralFMT
by:
(1)
refining
processing
technologies
(eg,
lyophilisation)
enable
manufacturing
low-volume
formulations
reducing
burden
(2)
developing
delivery
improve
organoleptic
safeguard
targeted
colonic
release.
These
advancements
present
opportunities
expand
therapeutic
scope,
beyond
C.
infections,
towards
conditions
requiring
frequent
dosing
regimens.
While
this
primarily
focuses
on
optimising
delivery,
it
is
important
contextualise
within
broader
shift
defined
consortia.
Live
biotherapeutic
products
(LBPs)
offer
an
alternative
approach,
interplay
between
LBPs
in
practice
remains
unresolved.
We
postulate
continued
innovation
multidisciplinary
approach
can
further
increase
efficacy
scalability
by
enabling
disease
site
targeting,
co-delivery
compounds
overcoming
colonisation
resistance.
Realising
goals
positions
cornerstone
personalised
care
across
range
diseases
rooted
microbiome
health.
Язык: Английский
Altered Expression of Intestinal Tight Junctions in Patients with Chronic Kidney Disease: A Pathogenetic Mechanism of Intestinal Hyperpermeability
Biomedicines,
Год журнала:
2024,
Номер
12(2), С. 368 - 368
Опубликована: Фев. 5, 2024
Background:
Systemic
inflammation
in
chronic
kidney
disease
(CKD)
is
associated
(as
a
cause
or
effect)
with
intestinal
barrier
dysfunction
and
increased
gut
permeability,
mechanisms
not
yet
fully
understood.
This
study
investigated
different
parameters
of
the
CKD
patients,
especially
tight
junction
(TJ)
proteins
their
possible
association
systemic
endotoxemia
inflammation.
Methods:
Thirty-three
patients
stage
I–IV
(n
=
17)
end-stage
(ESKD)
16)
11
healthy
controls
underwent
duodenal
biopsy.
Samples
were
examined
histologically,
presence
CD3+
T-lymphocytes
expression
occludin
claudin-1
epithelium
was
evaluated
by
means
immunohistochemistry,
circulating
endotoxin
concentrations
determined
ELISA
cytokines
IL-1β,
IL-6,
IL-8,
IL-10
TNF-α
serum
measured
using
flow
cytometry.
Results:
Patients
ESKD
had
significantly
higher
endotoxin,
IL-8
levels
compared
to
controls.
Intestinal
decreased,
inversely
correlated
endotoxemia.
Regarding
occludin,
specific
pattern
observed,
gradually
increasing
loss
its
from
crypt
tip
villi.
Conclusion:
The
enterocytes
reduced
CKD,
contributing
inflammatory
responses
these
patients.
Язык: Английский
Fecal microbiota transplantation as a possibility of curing Irritable Bowel Syndrome FMT as a possibility of curing IBS
Progress in Health Sciences,
Год журнала:
2024,
Номер
14(1), С. 41 - 49
Опубликована: Июнь 19, 2024
Introduction
and
Objective.
Irritable
Bowel
Syndrome
(IBS)
became
recently
a
common
problem
among
the
population
of
highly
developed
countries.
Most
patients
suffer
from
chronic
abdominal
pain
various
bowel
habit
disorders.
Although
pathogenesis
IBS
was
not
yet
entirely
defined,
intestinal
dysbiosis
is
frequently
mentioned
as
one
most
possible
mechanisms.
There
may
be
way
to
permanently
cure
IBS,
by
replacing
patient’s
dysbiotic
microflora
with
Fecal
Microbiota
Transplantation
(FMT)
healthy
donor.
The
purpose
this
paper
present
FMT
method
treatment.Review
methods.
Search
using
PubMed
database
combined
keywords:
"Irritable
Syndrome",
"Fecal
Transplantation",
"Dysbiosis"
"Intestinal
Microbiota".
An
attempt
made
comprehensive
state
knowledge
while
indicating
areas
that
require
further
research.
Brief
description
knowledge.
Effectiveness
in
has
been
clinically
proven
seems
donor-dependent.
Superdonor’s
microbiota
profile
defined
yet.
gradually
gaining
popularity
new
research
appears
confirming
long-term
effectiveness
procedure.Summary.
Research
results
are
promising
it
likely
will
introduced
treatment
routinely
used
clinical
practice.
Differences
test
related
use
material
donors.
It
important
establish
exact
dosage,
frequency
procedure,
criteria
for
selecting
superdonors,
if
more
than
donor
should
used,
other
things.
Язык: Английский
Fecal microbiota transplantation for glaucoma; a potential emerging treatment strategy
Current Research in Microbial Sciences,
Год журнала:
2024,
Номер
7, С. 100314 - 100314
Опубликована: Янв. 1, 2024
Glaucoma
is
the
primary
cause
of
irreversible
blindness
globally.
Different
glaucoma
subtypes
are
identified
by
their
underlying
mechanisms,
and
treatment
options
differ
its
pathogenesis.
Current
management
includes
topical
medications
to
lower
intraocular
pressure
surgical
procedures
like
trabeculoplasty
drainage
implants.
Fecal
microbiota
transplantation
(FMT)
an
almost
effective
safe
option
for
recurrent
Clostridium
difficile
infection.
The
relationship
between
bacterial
populations,
metabolites,
inflammatory
pathways
in
retinal
diseases
indicates
possible
therapeutic
strategies.
Thus,
incorporating
host
microbiota-based
therapies
could
offer
additional
patients.
Here,
we
propose
that
combining
FMT
with
standard
treatments
may
benefit
those
affected
this
condition.
Also,
potential
safety,
efficacy,
cost-effectiveness
clinical
applications
discussed.
Язык: Английский
Freeze-dried fecal microorganisms as an effective biomaterial for the treatment of calves suffering from diarrhea
Scientific Reports,
Год журнала:
2024,
Номер
14(1)
Опубликована: Ноя. 14, 2024
Fecal
microbiota
transplantation
(FMT)
is
a
therapeutic
modality
for
treating
neonatal
calf
diarrhea.
Several
practical
barriers,
including
donor
selection,
fecal
collection,
and
limited
timeframe
FMT,
are
the
main
constraints
to
using
fresh
feces
implementing
on-farm
FMT.
We
report
utility
of
FMT
with
pretreated
ready-to-use
frozen
(F)
or
freeze-dried
(FD)
microorganisms
In
total,
19
(F-FMT,
n
=
10
FD-FMT,
9)
treatments
were
conducted.
Both
100%
clinically
effective;
however,
multi-omics
analysis
showed
that
FD-FMT
was
superior
F-FMT.
Machine
learning
SourceTracker
confirmed
retained
four
times
better
in
recipient
calves
treated
than
A
predictive
model
based
on
receiver
operating
characteristic
curve
area
under
more
discriminative
F-FMT
observed
changes
metabolites
during
disease
recovery.
These
results
provide
new
insights
into
establishing
methods
preparing
increase
quality
animals
may
contribute
humans.
Язык: Английский